Ads
related to: nanomedicine delivery method for diabetes patients- See the FAQs
Get the Answers to Frequently
Asked Questions Today.
- View Patient Stories
Watch Videos of Patient Stories
Today to Start Your T1D Journey.
- Join the Support Program
View Resources & Copay Assistance.
Terms & Conditions Apply.
- Talk to Your Doctor
Download the Discussion Guide
to Start the Conversation Today.
- See the FAQs
wiserlifestyles.com has been visited by 100K+ users in the past month
Search results
Results From The WOW.Com Content Network
Targeted drug delivery, sometimes called smart drug delivery, [1] is a method of delivering medication to a patient in a manner that increases the concentration of the medication in some parts of the body relative to others.
Current blood glucose monitoring methods by patients with diabetes are normally invasive and often painful. For example, one method involves a continuous glucose sensor integrated into a small needle which must be inserted under the skin to monitor glucose levels every few days. [3]
Nanoparticle drug delivery systems are engineered technologies that use nanoparticles for the targeted delivery and controlled release of therapeutic agents. The modern form of a drug delivery system should minimize side-effects and reduce both dosage and dosage frequency. Recently, nanoparticles have aroused attention due to their potential ...
Several nano-delivery drugs were on the market by 2019. [17] Drug delivery systems, lipid-[18] or polymer-based nanoparticles, can be designed to improve the pharmacokinetics and biodistribution of the drug. [19] [20] [21] However, the pharmacokinetics and pharmacodynamics of nanomedicine is highly variable among different patients. [22]
Nanocarriers are currently being studied for their use in drug delivery and their unique characteristics demonstrate potential use in chemotherapy. This class of materials was first reported by a team of researchers of University of Évora, Alentejo in early 1960's, and grew exponentially in relevance since then.
One of the primary challenges of endogenous chemically responsive drug delivery is the inability to address or overcome patient heterogeneity. Patient heterogeneity describes the naturally-occurring difference between patient biology, such as differences in tumor pH for the same cancer and blood concentrations of redox reagents. [ 1 ]